 | Up a level |
Haddad, Robert; Guigay, Joel; Keilholz, Ulrich; Clement, Paul M; Fayette, Jérôme; de Souza Viana, Luciano; Rolland, Frédéric; Cupissol, Didier; Geoffrois, Lionnel; Kornek, Gabriela; Licitra, Lisa; Melichar, Bohuslav; Ribaldo Nicolau, Ulisses; Rauch, Daniel; Zanetta-Devauges, Sylvie; Cohen, Ezra E W; Machiels, Jean-Pascal; Tahara, Makoto; Vermorken, Jan; Geng, Yuan; ... (2019). Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trial. Oral oncology, 97, pp. 82-91. Elsevier 10.1016/j.oraloncology.2019.08.004
van den Bent, Martin J; Baumert, Brigitta; Erridge, Sara C; Vogelbaum, Michael A; Nowak, Anna K; Sanson, Marc; Brandes, Alba Ariela; Clement, Paul M; Baurain, Jean Francais; Mason, Warren P; Wheeler, Helen; Chinot, Olivier L; Gill, Sanjeev; Griffin, Matthew; Brachman, David G; Taal, Walter; Rudà, Roberta; Weller, Michael; McBain, Catherine; Reijneveld, Jaap; ... (2017). Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. Lancet, 390(10103), pp. 1645-1653. Elsevier 10.1016/S0140-6736(17)31442-3
